Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe ClinicalTrials.gov record for the lenvatinib and pembrolizumab thyroid cancer study is displayed, with its study details, eligibility criteria, outcomes, locations, and documents.SummaryDifference67%

- Check19 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner was added announcing NIH website changes and saying that “Super Intelligence” may appear in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site revision label in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now displays a 403 Forbidden error rather than the study details, indicating access is blocked or restricted. This prevents viewing the trial information while the underlying data remains unchanged.SummaryDifference20%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.